A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Registration Number
- NCT01106781
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 591
Inclusion Criteria
- Histological diagnosed as adenocarcinoma type of non-small cell lung cancer
- Have completed lung cancer operation
- The tumour EGFR gene mutation status test was performed as regular medical practice
Exclusion Criteria
- Patients who disagree to participate this study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method type and prevalence of EGFR mutation up to 3 months
- Secondary Outcome Measures
Name Time Method Operation type and adjuvant treatment type up to 3 months Disease Free Survival rate up to 3 months
Trial Locations
- Locations (1)
Research Site
🇨🇳Hangzhou, Zhejiang, China